Grand Rounds

Fridays from 12:00 to 1:15pm at WisPIC in the Commons Room 1616, unless otherwise noted.

Ryan Herringa, MD, PhD

Friday, August 4, 2018

Trauma, PTSD, and Neurodevelopment in Youth

Ryan Herringa, MD, PhD is an Assistant Professor in the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is a pediatric psychiatrist and neuroscientist whose work explores the neural substrates of childhood traumatic stress and PTSD. He directs the BRAVE Lab (Building Resilience after Adversity and Violent Events), which seeks to map neurodevelopmental trajectories following childhood trauma. Specifically, the BRAVE Lab uses structural and functional neuroimaging combined with behavioral, physiological, and genetic approaches to develop biomarkers of vulnerability, recovery, and resilience to childhood trauma. Biomarkers of childhood trauma could then be used to improve prevention and intervention strategies in victimized youth. In addition to his research, Dr. Herringa remains active in clinical care and teaching, with specilization in the treatment of youth with trauma-related mental illness.

Amit Etkin, MD, PhD

Friday, September 29, 2018

A Circuits-First Approach to Mental Illness

Amit Etkin, MD, PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford, a member of the Stanford Neurosciences Institute, and an Investigator at the Palo Alto VA. He is trained both as a neuroscientist and psychiatrist. The overarching aim of the Etkin Lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions. In support of this goal, Dr. Etkin also collaborates with other neuroscientists, engineers, psychologists, physicians, and others at Stanford to establish a new intellectual, scientific, and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease.

Clint Kilts, PhD

Friday, November 10, 2018

The Acquired Brain States of Human Drug Addiction

Clint Kilts, PhD received his postgraduate trainin in psychopharmacology and neurochemistry in the Department of Pharmacology and Toxicology at Michigan State University. He continued his training in neuropharmacology, analytical neurochemistry, and human psychopharmacology in the Biological Sciences Research Center at the University of North Carolina. He subsequently joined the faculties of the Departments of Psychiatry and Pharmacology at Duke University where he served as Director of the Clinical Pscyhopharmacology Laboratory. In 1992, Dr. Kilts joined the faculty of the Department of Psychiatry and Behavioral Sciences in the Emory University School of Medicine. At Emory, he served as the Interim Director of the Center for PET and in 2000 became the first Vice Chair for Research for the Department of Psychiatry and Behavioral Sciences. In 2009, he joined faculty in the Department of Psychiatry and Behavioral Sciences in the College of Medicine at the University of Arkansas for Medical Sciences (UAMS). He is the founding director of the Brain Imaging Research Center (BIRC) in the UAMS Psychiatric Research Institute (PRI) and an Associate Director of the PRI. He has a long record of NIH-funded research, most recently in the use of in vivo brain functional, molecular, and connectivity imagingto explore the neural network processing basis of human behavior. With a focus on drug abuse and addiction, he has a clinical research focus on the use of neuroimaging technology to define the brain basis of psychiatric disorders and their treatment. Dr. Kilts received the Wilbur Mills Chair in Alcohol and Drug Abuse prevention in 2014. Additional academic accomplishments relate to organizational research planning, organization, and mentoring. His current goals as Director of the BIRC are to extend magnetic resonance imaging (MRI)-based technology and human neuroscience to areas of clinical problem solving in psychiatry and related disciplines within the PRI and at UAMS.

Carlos Schenck, MD

Monday, December 4, 2018

What Should Psychiatrists Know About the Parasomnias?

Carlos H. Schenck was born in New York City in 1951, received his B.A. degree from the Johns Hopkins University in 1972, and his M.D. degree from the State University of New York at Buffalo in 1976. He completed a Psychiatry Residency at the University of Minnesota in 1980, where he is currently a Professor and senior staff psychiatrist at the Hennepin County Medical Center in Minneapolis. Since 1982 he has been on staff at the Minnesota Regional Sleep Disorders Center. In 1985-7 Dr. Schenck and colleagues reported on a new category of dream-enacting Parasomnia that they named REM sleep behavior disorder (RBD). In 1996 Dr. Schenck and colleagues first reported that RBD commonly heralds future parkinsonism, thus initiating a major international clinical and basic research effort in this area. In 2009 Dr. Schenck was the Founding President of the International REM Sleep Behavior Disorder Study Group that has held yearly research symposia and that has published collaborative, multicenter, peer-reviewed publications.

Dr. Schenck and colleagues also identified and named Sleep Related Dissociative Disorder in 1989; Sleep Related Eating Disorder in 1991; Status Dissociatus (mixed states of REM sleep, NREM sleep and wake in 1991; Epic Dream Disorder in 1995; Parasomnia Overlap Disorder (RBD linked comorbid with the Non-REM sleep parasomnias Sleepwalking and Sleep Terrors) in 1997;and formulated the first classification of Sexsomnia (abnormal sexual behaviors during sleep) in 2007.

Dr. Schenck and colleague Mark W. Mahowald, M.D. received the “William C. Dement Academic Achievement Award” from the American Academy of Sleep Medicine (AASM) in June 2007, for discovering RBD and other parasomnias. Drs. Schenck and Mahowald received the Sleep Research Society “Outstanding Scientific Achievement Award” in June 2010 for their discovery of RBD and other parasomnias, and also for identifying the strong link of RBD with parkinsonian disorders and with narcolepsy-cataplexy. Drs. Schenck and Mahowald received the "Sleep Science Award" from the American Academy of Neurology (AAN) during the annual AAN meeting in Boston on April 24, 2018 for their discovery of RBD and for the strong link of RBD with parkinsonian disorders.

Drs. Schenck and Mahowald identified and described the medical-legal entities “Parasomnia Pseudo-Suicide” and “Parasomnia With (Intermittent) State-Dependent Danger as a Non-Insane Automatism," and have published extensively on the medical-legal aspects of Parasomnias. They were the founders, along with colleague Michel Cramer Bornemann, M.D. of Sleep Forensic Associates in 2007.

Dr. Schenck was Co-Chair of the Parasomnias Committee for The International Classification of Sleep Disorders-2nd Edition (ICSD-2) (AASM, 2005), and was a member of the Parasomnias Committee for the ICSD-3 published in March 2014. He is an Associate Editor of the journal Sleep, he is on the Editorial Board of the journal Sleep Science, and he is on the Executive Committee of the World Association of Sleep Medicine and the World Sleep Society. The August 2013 issue of the journal Sleep Medicine was devoted exclusively to RBD original research and review articles written by basic scientists and clinicians, with Dr. Schenck serving as a Guest Co-Editor of that issue. Dr. Schenck is the Editor of the first textbook on RBD (with 46 chapters written by clinical and basic science investigators) that will be published by Springer in early 2018.

Dr. Schenck’s first book was “Paradox Lost: Midnight in the Battleground of Sleep and Dreams” (Extreme-Nights, LLC, Minneapolis, MN, 2005). His second book was “Sleep: The Mysteries, The Problems, and The Solutions (Penguin/Avery Press, 2007). On June 3, 2011 Dr. Schenck was one of three participants in the symposium, “The Mind After Midnight: Where Do You Go When You Go To Sleep?” that took place during the 4th annual World Science Festival in New York City.

Dr. Schenck has appeared regularly on national television and radio news programs, such as CNN, ABC-TV (20/20, Good Morning America, Nightline, Prime Time [Medical Mysteries Series]), the Oprah Winfrey Show (1997, 2008), CBS-TV, NBC-TV "48 Hours", Discovery Channel, Learning Channel, National Public Radio etc. Dr. Schenck’s research has been described in articles appearing in the New York Times, Wall Street Journal, Newsweek, National Geographic Magazine, Associated Press, US News & World Report, Reader's Digest, and other national and international (International Herald Tribune, Stern magazine, China Times) publications.

Kerry J. Ressler, MD, PhD

Friday, January 12, 2018

Understanding Fear and PTSD: From Cells and Circuits to Behavior

Kerry J. Ressler, MD, PhD is the James and Patricia Poitras Chair in Psychiatry, and Chief of the Division of Depression and Anxiety Disorders at McLean Hospital, affiliate of the Harvard Medical School.  Previously he spent 18 years at Emory University and Grady Memorial Hospital in Atlanta, where he led the Grady Trauma Project, a study focused on understanding the Psychology, Biology, and Trauma-Related factors contributing to Posttraumatic Stress Disorder, Substance Abuse and Violence in over 10,000 participants from urban Atlanta.  He is also the 2018 President-Elect of the US Society for Biological Psychiatry. He received his Bachelor of Science degree in molecular biology from M.I.T., and his M.D./Ph.D. from Harvard Medical School. In 1992 at Harvard, he was the first student of Dr. Linda Buck (Nobel Prize, 2004), helping to identify the molecular organization of the olfactory receptor system.  Dr. Ressler is a previous Investigator of the Howard Hughes Medical Institute and a current member of the National Academy of Medicine.  His work focuses on translational research bridging molecular neurobiology in animal models with human genetic research on emotion, particularly fear and anxiety disorders.  He has published over 230 manuscripts ranging from basic molecular mechanisms of fear processing to understanding how emotion is encoded in the brain across animal models and human patients.  

Diego Pizzagalli, PhD

Friday, March 9, 2018

The Neuroscience of Major Depression: Focus on Anhedonia

Diego Pizzagalli, PhD received his M.A. (1995) and Ph.D. (1998) from the University of Zurich, Switzerland and did post-doctoral work at University of Wisconsin, Madison. From 2002-2010 he was a faculty member in the Department of Psychology at Harvard University, where he served as the John and Ruth Hazel Associate Professor of the Social Sciences. In 2010, he was recruited to McLean Hospital to serve as the Founding Director of the newly established Center for Depression, Anxiety and Stress Research (CDASR), as well as the Director of the McLean Imaging Center (MIC). Since September 2015, he also serves as the Director of Research for the Division of Depression and Anxiety. He is currently a Professor of Psychiatry at Harvard Medical School.

The main goals of his research are to improve our understanding of the psychological, environmental, and neurobiological factors associated with mood disorders, particularly major depression. To this end, he integrates behavioral, electrophysiological, neuroimaging, and, more recently, molecular genetics approaches to investigate three putative endophenotypes of depression: anhedonia (loss of pleasure), increased stress sensitivity, and negative processing biases.

Dr. Pizzagalli has published over 150 papers and chapters and serves on the editorial board of 10 journals. Among several awards, he received the Distinguished Scientific Award for an Early Career Contribution to Psychophysiology from the Society for Psychophysiological Research (2006), the Early Career Award from the EEG and Clinical Neuroscience Society (2007), the Anne M. Cataldo Excellence in Mentoring Award from McLean Hospital (2015), a MERIT award from the National Institute of Mental Health (2018), and The Stuart T. Hauser, M.D. PhD. Mentorship Award in Psychiatry from Harvard Medical School (2018).

Mary Phillips, MD, MD

Friday, April 27, 2018

Multimodal Neuroimaging - Neural Circuits and Mood Disorders: Toward Neural Biomarkers for Novel Interventions

Mary Phillips, MD, MD is the Pittsburgh Foundation-Emmerling Endowed Chair in psychotic Disorders, and Professor in Psychiatry and Clinical and Translational Science in the University of Pittsburgh. She heads the Clinical and Translational Affective Neuroscience Program in the Department of Psychiatry at the University of Pittsburgh. Dr. Phillips’ research focuses on using multimodal neuroimaging techniques to elucidate functional and structural abnormalities in emotion processing, reward processing and emotional regulation circuitries that are associated with specific psychiatric disorders, and symptom dimensions in individuals with mood and anxiety disorders. Her research also focuses on identifying the neurodevelopmental trajectories in these circuitries that are associated with the development of such disorders in youth and infants, and the extent to which these neuroimaging techniques can identity biomarkers reflecting underlying pathophysiologic processes that denote future risk for these disorders in as yet unaffected youth. Her more recent work examines how neuromodulation techniques can be targeted on identified neural biomarkers of mood disorders, as a step toward developing new interventions for individuals with these disorders. She works in collaboration with basic neuroscientists in translational studies of neural circuitry abnormalities in these disorders.

Dr. Phillips trained in Medicine at Cambridge University, UK, and in Psychiatry at the Maudsley Hospital and the Institute of Psychiatry, King’s College, University of London, UK. She joined the Department of Psychiatry at the University of Pittsburgh as a full-time faculty member in July, 2005. In 2005, Dr. Phillips became a member of the American College of Neuropsychopharmacology; in 2006, she was awarded the Nellie Blumenthal Independent Investigator Award by the Brain and Behavior Research Foundation (National Alliance for Research in Schizophrenia and Depression); in 2012, became a Fellow of the American College of Neuropsychopharmacology; and, in 2014, she became a member of the American Society of Clinical Investigation and received the Joel Elkes Research Prize of the American College of Neuropsychopharmacology. In 2018, she became President Elect of the Society of Biological Psychiatry, has served on the Membership Committee of the American College of Neuropsychopharmacology, and on Program Committees of both the Society of Biological Psychiatry and the American College of Neuropsychopharmacology. In 2018, she was elected to the Scientific Council of the Brain and Behavior Research Foundation, and received the Brain and Behavior Research Foundation Colvin Prize for research in mood disorders in 2018.

Dr. Phillips has received research funding awards from the National Institute of Mental Health and the Brain and Behavior Research Foundation in the U.S., and the Medical Research Council and the Wellcome Trust in the UK. Dr. Phillips has mentored over 60 junior investigators, including being mentor to 11 K awardees, has extensive national and international collaborations, and has authored or co-authored more than 300 publications.

Bunmi O. Olatunji, PhD

Friday, June 8, 2018

The Psychopathology of Disgust in Obsessive-Compulsive Disorder

Bunmi O. Olatunji, PhD is Professor in the Department of Psychology and Psychiatry at Vanderbilt University where he also serves as the Director of Clinical Training. He is Associate Editor of the Journal of Consulting and Clinical Psychology and currently serves on the editorial boards of Behavior Therapy, International Journal of Cognitive Therapy, Journal of Obsessive-Compulsive and Related Disorders, Psychological Bulletin, Psychological Assessment, and Psychotherapy. He has published more than 160 journal articles and book chapters, and has participated in more than 100 conference presentations. He is co-author of the book “10-minute CBT: Cognitive behavioral interventions for the brief medication visit” published by Oxford Press and co-editor of the book “Disgust and its disorders: Assessment, theory, and treatment” published by the American Psychological Association.

As Director of the Emotion and Anxiety Research Laboratory at Vanderbilt University, his primary research interest involves multilevel examination of cognitive behavioral theory, assessment, and therapy for anxiety disorders. He is currently adopting an experimental psychopathology framework to examine the role of basic emotions, especially disgust, as they relate to the assessment, etiology, and maintenance of anxiety-related disorders. His research has been funded by the National Institute of Health and the Anxiety Disorders Association of America. For his research and professional efforts, he had been the recipient of the American Psychological Association (APA) Division 12 David Shakow Early Career Award for Distinguished Scientific Contributions to Clinical Psychology, the Association for the Advancement of Behavioral and Cognitive Therapies New Researcher Award, and the APA Division 12 Theodore Blau Early Career Award for Distinguished Professional Contributions to Clinical Psychology. He was also the recent recipient of the APA Distinguished Scientific Awards for an Early Career Contribution to Psychology. This award recognizes excellent psychologists who are at early stages of their research careers.

Andrew H. Miller, MD

Friday, August 3, 2018

Inflammation and Depression: Mechanisms, Mediators and Therapeutic Implications

Andrew Miller, MD is William P. Timmie Professor of Psychiatry and Behavioral Sciences at the Emory University School of Medicine in Atlanta, Georgia. He is also the Vice Chair for Research in the Department of Psychiatry and Behavioral Sciences and Director of the Emory Behavioral Immunology Program. Finally, Dr. Miller is the co-leader of the Cancer Prevention and Control Research Program Research at the Winship Cancer Institute. Dr. Miller is an internationally recognized leader in the area of brain-immune interactions as they relate to depression in medically healthy as well as medically ill patients including patients with cancer. His work has demonstrated that during immune activation, inflammatory cytokines can access the brain and interact with the metabolism of dopamine and glutamate, while altering neurocircuits in the brain relevant to motivation and reward as well as anxiety and alarm. Dr. Miller has also studied the impact of cytokines on neuroendocrine regulation and sleep including the study of the specific signal transduction pathways involved. Additionally, Dr. Miller and his group conducted the first clinical trial examining the efficacy of a cytokine antagonist for the treatment of depression. He has produced over 200 scholarly publications and edited a book entitled Depressive Disorders and Immunity. Dr. Miller’s research awards include the Curt Richter Award from the International Society of Psychoneuroendocrinology and the Norman Cousins Award from the Psychoneuroimmunology Research Society. Aside from his research endeavors, Dr. Miller has won numerous teaching and mentoring awards and is a Board Certified Psychiatrist and past examiner for the American Board of Psychiatry and Neurology.

Daniel Pine, MD

Friday, September 28, 2018

Title TBD

*** Dr. Pine will also be delivering the Greenfield Memorial Lecture on Thursday, September 27, 2018 at 5:30pm ***

Melissa DelBello, MD, MS

Friday, November 30, 2018

Neuropharmacology of Bipolar Disorder in Youth

Melissa Delbello, MD, MS, has served as professor and chair of the Department of Psychiatry and Behavioral Neuroscience since 2014. She joined the University of Cincinnati College of Medicine faculty in 2000 as an assistant professor of psychiatry and pediatrics. Dr. DelBello has served in several leadership roles in the Department of Psychiatry and Behavioral Neuroscience, including vice chair of clinical research since 2007 and co-director of the Division of Bipolar Disorders Research since 2004. She has also been co-director of the Mood Disorders Center at the UC Gardner Neuroscience Institute. A nationally recognized expert on child and adolescent mood disorders, Dr. DelBello has lectured and published extensively on bipolar disorder and served as principal or co-investigator of several NIH grants. She has been a member of the Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section of the Center for Scientific Review at the National Institutes of Health since 2009, most recently serving as chairperson for a term running from July 2012 through June 2014. Since 2012 she has chaired the Research Committee of the American Academy of Child and Adolescent Psychiatry. At UC Medical Center, she has served as medical director of the Resident Mood Medication Clinic since its launch in September 2013. She is co-director of the Mood Disorders Program at Cincinnati Children’s Hospital Medical Center. Dr. DelBello is a fellow of the American Academy of Child and Adolescent Psychiatry and also holds membership in the American Psychiatric Association, International Society for Bipolar Disorders and American College of Neuropsychopharmacology. A native of New York City, Dr. DelBello received her bachelor of science degree with honors from Cornell University and her medical degree with honors from the University of Rochester School of Medicine. She completed residencies in psychiatry at Cornell Medical Center (1995-96) and the UC College of Medicine (1996-98). In addition, she holds a master’s in epidemiology and biostatistics from UC.